CL2020003257A1 - Compuestos antagonistas de pcsk9. - Google Patents

Compuestos antagonistas de pcsk9.

Info

Publication number
CL2020003257A1
CL2020003257A1 CL2020003257A CL2020003257A CL2020003257A1 CL 2020003257 A1 CL2020003257 A1 CL 2020003257A1 CL 2020003257 A CL2020003257 A CL 2020003257A CL 2020003257 A CL2020003257 A CL 2020003257A CL 2020003257 A1 CL2020003257 A1 CL 2020003257A1
Authority
CL
Chile
Prior art keywords
antagonist compounds
pcsk9 antagonist
pcsk9
compounds
macroclyclic
Prior art date
Application number
CL2020003257A
Other languages
English (en)
Inventor
Chengwei Wu
Elisabetta Bianchi
Harold B Wood
Hubert B Josien
Thomas Joseph Tucker
Angela Dawn Kerekes
Ling Tong
Abbas M Walji
Anikumar G Nair
Fa-Xiang Ding
Danila Branca
Yusheng Xiong
Sookhee Nicole Ha
Jian Liu
Sobhana Babu Boga
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2020003257A1 publication Critical patent/CL2020003257A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPUESTOS MACROCLÍCLICOS, ANTAONISTAS DE PCSK9; UNA COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA.
CL2020003257A 2018-06-21 2020-12-16 Compuestos antagonistas de pcsk9. CL2020003257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
CL2020003257A1 true CL2020003257A1 (es) 2021-07-23

Family

ID=67263083

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020003257A CL2020003257A1 (es) 2018-06-21 2020-12-16 Compuestos antagonistas de pcsk9.
CL2022000027A CL2022000027A1 (es) 2018-06-21 2022-01-05 Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000027A CL2022000027A1 (es) 2018-06-21 2022-01-05 Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).

Country Status (38)

Country Link
US (3) US11427616B2 (es)
EP (2) EP3810626B1 (es)
JP (3) JP7112531B2 (es)
KR (2) KR20250161677A (es)
CN (2) CN121130044A (es)
AR (1) AR115597A1 (es)
AU (2) AU2019290163C1 (es)
BR (1) BR112020025274A8 (es)
CA (1) CA3102629A1 (es)
CL (2) CL2020003257A1 (es)
CO (1) CO2021000456A2 (es)
CR (1) CR20210031A (es)
DK (1) DK3810626T3 (es)
DO (1) DOP2020000250A (es)
EA (1) EA202190086A1 (es)
EC (1) ECSP21003643A (es)
ES (1) ES3047399T3 (es)
FI (1) FI3810626T3 (es)
GE (2) GEP20237506B (es)
HR (1) HRP20251302T1 (es)
HU (1) HUE073367T2 (es)
IL (2) IL321719A (es)
JO (1) JOP20190150A1 (es)
LT (1) LT3810626T (es)
MA (1) MA52967B1 (es)
MD (1) MD3810626T2 (es)
MX (1) MX2020013726A (es)
NI (1) NI202000101A (es)
PE (1) PE20211584A1 (es)
PH (1) PH12020552187A1 (es)
PL (1) PL3810626T3 (es)
PT (1) PT3810626T (es)
RS (1) RS67338B1 (es)
SG (1) SG11202012451WA (es)
SI (1) SI3810626T1 (es)
TW (1) TWI840376B (es)
UA (1) UA129467C2 (es)
WO (1) WO2019246349A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
IL321719A (en) 2018-06-21 2025-08-01 Merck Sharp ַ& Dohme Llc Pcsk9 antagonist compounds
WO2019246386A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246352A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Pcsk9 antagonist bicyclo-compounds
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
EP3810177B1 (en) 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
US11505575B2 (en) 2018-06-21 2022-11-22 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
WO2021041770A1 (en) * 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑
MX2024002146A (es) 2021-08-19 2024-03-08 Merck Sharp & Dohme Llc Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
EP4540267B1 (en) 2022-06-15 2026-04-15 Merck Sharp & Dohme LLC Cyclic peptides for trapping interleukin-1 beta
CN119731194A (zh) * 2022-08-17 2025-03-28 默沙东有限责任公司 Pcsk9抑制剂的结晶形式、组合物及用途
EP4727552A2 (en) * 2023-06-15 2026-04-22 Merck Sharp & Dohme LLC Passive permeable pcsk9 antagonist compounds
US20250152658A1 (en) 2023-11-14 2025-05-15 Merck Sharp & Dohme Llc Cyclic peptide for trapping interleukin-1 beta
WO2025128805A1 (en) 2023-12-15 2025-06-19 Merck Sharp & Dohme Llc A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2025264781A1 (en) * 2024-06-18 2025-12-26 Kemira Oy J Cationizing agents for saccharides and methods
WO2026019624A1 (en) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Synthesis of cyclic oligopeptides
WO2026019622A1 (en) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Crystal forms of a cyclictetrapeptide and processes for preparing
WO2026032253A1 (zh) * 2024-08-06 2026-02-12 石药集团中奇制药技术（石家庄）有限公司 环肽类似物及其制备方法和用途
WO2026034639A1 (ja) * 2024-08-09 2026-02-12 株式会社Spin Wave ペプチド合成用可溶性担体およびこれを用いた合成方法
CN119930471A (zh) * 2024-12-31 2025-05-06 苏州默迪夫生物科技有限公司 Mk-a的制备方法、所用的中间体及其合成方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
US4656269A (en) 1986-04-15 1987-04-07 Kissei Pharmaceutical Co., Ltd. Histidine derivatives
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO2000014095A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
JP2004513076A (ja) 2000-07-25 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病治療で有用なｎ−置換インドール類
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
JP4340232B2 (ja) 2002-08-29 2009-10-07 メルク エンド カムパニー インコーポレーテッド 抗糖尿病活性を有するインドール類
WO2004066963A2 (en) 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
EP2174343A1 (en) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Manufacturing method of semiconductor device
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
KR101510975B1 (ko) 2010-12-28 2015-04-10 카딜라 핼쓰캐어 리미티드 이상지질혈증의 치료에 적절한 헤테로시클릭 화합물
KR20140006022A (ko) * 2011-02-11 2014-01-15 아이알엠 엘엘씨 Pcsk9 길항제
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
KR20150000461A (ko) 2011-10-27 2015-01-02 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
SG11201505856TA (en) 2013-03-14 2015-08-28 Daiichi Sankyo Co Ltd Novel binding proteins for pcsk9
JP2016512825A (ja) 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションＳｈｉｆａ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法
ES2914978T3 (es) 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
US10557129B2 (en) 2015-01-30 2020-02-11 Pronasci Inc. Peptides derived from human PCSK9 catalytic domain and uses thereof for promoting LDL-R activity
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
CN107286158A (zh) 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
EP3442991A4 (en) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. RAS-BINDING PEPTIDES AND METHODS OF USE
CA3026823A1 (en) 2016-06-24 2017-12-28 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
US11977968B2 (en) 2017-04-20 2024-05-07 Shanghai Cambricon Information Technology Co., Ltd. Sparse processing in neural network processors
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
EP3810177B1 (en) 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246352A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Pcsk9 antagonist bicyclo-compounds
WO2019246386A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Cyclic polypeptides for pcsk9 inhibition
US11505575B2 (en) 2018-06-21 2022-11-22 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
IL321719A (en) 2018-06-21 2025-08-01 Merck Sharp ַ& Dohme Llc Pcsk9 antagonist compounds
WO2021041770A1 (en) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds

Also Published As

Publication number Publication date
JP7112531B2 (ja) 2022-08-03
SI3810626T1 (sl) 2025-12-31
BR112020025274A8 (pt) 2023-02-14
JP2022141879A (ja) 2022-09-29
DOP2020000250A (es) 2021-02-28
US20230159592A1 (en) 2023-05-25
AU2022259744B2 (en) 2024-07-11
MD3810626T2 (ro) 2025-12-31
GEAP202215540A (en) 2022-12-12
JP7855670B2 (ja) 2026-05-08
NI202000101A (es) 2021-05-28
FI3810626T3 (fi) 2025-10-21
US20190389909A1 (en) 2019-12-26
US20250206781A1 (en) 2025-06-26
EP3810626B1 (en) 2025-07-23
SG11202012451WA (en) 2021-01-28
AR115597A1 (es) 2021-02-03
IL321719A (en) 2025-08-01
KR102884527B1 (ko) 2025-11-13
ECSP21003643A (es) 2021-02-26
TW202019950A (zh) 2020-06-01
BR112020025274A2 (pt) 2021-03-09
HRP20251302T1 (hr) 2025-12-19
LT3810626T (lt) 2025-11-10
AU2019290163C1 (en) 2022-11-03
KR20210024035A (ko) 2021-03-04
JP2025041712A (ja) 2025-03-26
PE20211584A1 (es) 2021-08-18
US11427616B2 (en) 2022-08-30
MA52967B1 (fr) 2025-09-30
US12209145B2 (en) 2025-01-28
GEP20237506B (en) 2023-05-25
EA202190086A1 (ru) 2021-05-18
JOP20190150A1 (ar) 2019-12-21
UA129467C2 (uk) 2025-05-07
MX2020013726A (es) 2021-03-02
AU2022259744A1 (en) 2022-12-01
AU2019290163B2 (en) 2022-08-04
RS67338B1 (sr) 2025-11-28
EP3810626A1 (en) 2021-04-28
EP4660303A3 (en) 2026-02-25
CN112313243B (zh) 2025-09-02
IL279363B1 (en) 2025-08-01
EP4660303A2 (en) 2025-12-10
DK3810626T3 (da) 2025-08-18
PH12020552187A1 (en) 2021-07-26
PT3810626T (pt) 2025-10-15
PL3810626T3 (pl) 2025-12-22
TWI840376B (zh) 2024-05-01
CN112313243A (zh) 2021-02-02
CO2021000456A2 (es) 2021-01-29
ES3047399T3 (en) 2025-12-03
WO2019246349A8 (en) 2021-02-04
MA52967A (fr) 2021-04-28
CR20210031A (es) 2021-02-11
JP7607615B2 (ja) 2024-12-27
CL2022000027A1 (es) 2022-08-19
JP2021522311A (ja) 2021-08-30
AU2019290163A1 (en) 2021-01-07
HUE073367T2 (hu) 2026-01-28
WO2019246349A1 (en) 2019-12-26
CA3102629A1 (en) 2019-12-26
IL279363A (en) 2021-01-31
IL279363B2 (en) 2025-12-01
KR20250161677A (ko) 2025-11-17
CN121130044A (zh) 2025-12-16

Similar Documents

Publication Publication Date Title
CL2022000027A1 (es) Compuestos antagonistas de pcsk9. (divisional de solicitud 202003257).
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
MX418110B (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas
EP3770148C0 (en) RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING IT AND ITS USE
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
CR20210021A (es) Apirasas solubilizadas, métodos y usos
BR112018006206A2 (pt) composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EP3795166A4 (en) PHARMACEUTICAL COMPOSITION OF KOR RECEPTOR AGONIST
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
CL2022001393A1 (es) Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el
SV2019005811A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos